

RECEIVED  
CENTRAL FAX CENTER

JUN 24 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Graff et al.

Serial No. 10/627,451

Filed: July 25, 2003

For: Colorectal Neoplasia

Group Art Unit: 1623

Examiner: Khare, Devesh

Attorney Docket No. UTSD:0980

OFFICIAL

DECLARATION UNDER 37CFR1.132

I, Jonathan Michael Graff declare and state as follows:

1. I am an Associate Professor in Internal Medicine and Molecular Biology in the Graduate School of Biomedical Sciences at the University of Texas Southwestern Medical Center. I hold Ph.D. and M.D. degrees from Duke University. I have received numerous biomedical awards, including the American Cancer Society Scholar Award, and have authored many scientific papers in the field of cancer and cell biology. This application is assigned to my employer, the Board of Regents, University of Texas System, and I am a named inventor.

2. The claim phrase "determining a patient is subject or predisposed to colorectal neoplasia" is definite to those skilled in the art. Those skilled at diagnosing and treating patients with colorectal neoplasia know how to determine if a patient is subject or predisposed to colorectal neoplasia – that is their professional expertise. The Specification teaches that in particular embodiments, the subject patient has undergone removal or ablation of a colorectal neoplasia and is determined to be predisposed to colorectal neoplasia recurrence, including genetically predisposed to the development of colorectal neoplasia (Specification, p.4, lines 17-19); that preferred target patients are predetermined to have a personal or familial history of colorectal neoplasia, or are predetermined to be at relatively high risk of developing a colorectal neoplasia (Specification, p.4, lines 20-22); and that the determining step may comprise detecting an indication of or predisposition to polyps or colorectal cancer (Specification, p.4, lines 22-23). Those skilled in the art do not require further recital to understand and practice the determining

step recited in the claims.

The claims' relative terms such as "reducing development of," "reduced," "poor gut absorption," and "gut-beneficial culture" are also definite to those skilled in the art. The Specification provides detailed description of each of the recited relative terms. Furthermore, the claimed methods of "reducing" development of colorectal neoplasia expressly require that the development of colorectal neoplasia be "reduced" *as compared with otherwise similar non-treated patients*, (see, e.g. claim 1). Furthermore, detecting results whereby the development of the colorectal neoplasia is reduced as compared with otherwise similar non-treated patients is repeatedly exemplified. Specification, p.6, line 19 - p.7, line 10; p.7, lines 12 - 31; and p.8, lines 1-20.

The claims and Specification detail that the recited antibiotic provides poor gut absorption, similar to aminoglycoside antibiotics, such as neomycin. The Specification teaches that methods for modifying or delivering otherwise highly gut absorbable antibiotics to or in a poorly gut absorbable form are known in the art, and include gut-retaining chemical moieties, chelators, enteric coatings, etc.; see, *Remington's Pharmaceutical Science*, Mack Publishing Co, NJ (1991). In addition, suitable excipients or carriers and methods for preparing administrable compositions are known or apparent to those skilled in the art and are described in more detail in publications such as *Remington's*. Specification, p.5, lines 6-15.

The claim phrase "introducing into the gut an effective amount of a probiotic, gut-beneficial microbial culture" is definite to those skilled in the art. The Specification teaches embodiments of the invention which forestall or help avoid development of undesirable effects of antibiotic usage, such as side-effects, antibiotic resistance, etc. These embodiments adopt established procedures for minimizing development of side effects, resistance, etc. Specification, p.5, lines 16-19. In the immediate subsequent paragraph, the Specification teaches that in particular embodiments, the invention further comprises introducing into the gut an effective amount of a probiotic, gut-beneficial microbial culture (Specification, p.5, lines 28-29), and provides detailed description and exemplification of this embodiment. Hence, those skilled in the art would recognize the function provided by the probiotic, gut-beneficial microbial culture, and not confuse it with "an anti-neoplasia agent."

3. Flotte et al. (US Pat No. 5,614,502) describe administering therapeutic compounds in combination with high pressure impulse transients to treat diseases like neoplasms and inflammation. Flotte Col.3, lines 14-16, 26-28. The compounds are administered so as to be preferentially localized to the target tissue. Col.3, lines 40-44. Then, high pressure waves are generated (for example, by laser-induced ablation, Col.4, lines 20-25), which increase drug delivery to localized cells. Col.4, lines 57-60. Because the drugs have little effect in the absence of the high pressure impulse, there should be little toxicity outside the area of the tumor. Col.5, lines 11-14. The high pressure impulse works by increasing cell permeability, Col.5, lines 20-22.

Hu et al. (US Pat No. 6,482,802; see, also, Hu et al. paper, 1998, PNAS 95, 9791-795) report that neomycin was the only member of a panel of aminoglycoside antibiotics that was able to reduce angiogenin-induced cell proliferation and angiogenesis, as measured using cultured human endothelial cells and chick embryo chorioallantoic membranes (CAM). Streptomycin, kanamycin, gentamicin, amikacin, and paromomycin were found to lack anti-angiogenic activity. This Hu attributes to phospholipase C (PLC) inhibition because neomycin is the only aminoglycoside antibiotic of the panel tested that inhibits PLC, and because U-73122, another PLC inhibitor, similarly inhibited angiogenin-induced cell proliferation and angiogenesis. See abstract of Hu paper; col.20, lines 22-28, col.21, line 66 - col.22, line 8, and col.27, lines 8-27 of Hu patent. The Hu patent also reports that injected neomycin was able to reduce growth of cultured angiogenin-secreting tumor cells (Olson et al., Int J Cancer. 2002 Apr 20;98:923-9; Clin Cancer Res. 2001 Nov;7:3598-605) transplanted into mice; see, col.27, line 43 - col.29, line 10 of Hu patent.

From these findings, Hu suggests use of neomycin for treating any angiogenin-induced angiogenesis. The Hu patent purports applicability to all angiogenesis-related diseases, which are "myriad and varied" and "include, but are not limited to, various forms of neovascularization or hypervascularization diseases, inflammatory diseases, arthritis and cancer", and then goes on to recite a laundry-list of all major solid and blood-borne tumors, corneal and retinal diseases, inflammatory diseases, and various infectious diseases, including AIDS (col.16, line 56 - col.18, line 16). Among the 60+ recited solid tumors is colon cancer (col.17, lines 10-11).

Hu does not provide the public with any cure for cancer, inflammatory disease, arthritis, or AIDS. He has shown that neomycin can reduce angiogenin-induced angiogenesis and growth in

CAM and cultured cell models, and from these data, claims to be able to treat innumerable human diseases. In fact, anti-angiogenesis drugs have notoriously failed to live up to their promise as cancer therapies, primarily because there are dozens of alternative factors which can drive angiogenesis. Science Journal, WSJ, Jul 11, 2003. Furthermore, reports using azoxymethane (AOM) and 1,2-dimethyl hydrazine (DMH)-induced colon cancers have suggested neomycin is not a viable therapy for colon cancer, and may actually increase the incidence of colon adenocarcinomas (Reddy et al., 1984 JNCI 73, 275-9; Panda et al., 1999, Br J Cancer 80, 1132-6).

With the recent development of colon cancer animal models based on defined genetic lesions (e.g. Zhu et al., Cell 1998, 94, 703-714), the use of chemical carcinogenesis models like AOM and DMH has become less favored (Boivin et al., Gastroenterology 2003, 124, 762-777). Hence, a recent review of colon cancer chemoprevention surveys the many agents reported to influence intestinal tumors, and does not include any antibiotics; see, Table 1 of Corpet et al., Cancer Epidemiology, Biomarkers & Prevention 2003, 12, 391-400. Work in colon cancer animal models has suggested that intestinal neoplasia is independent of gut microbial status (Dove et al., Cancer Res 1997, 57, 812-14).


In any event, the proposed combination is inapplicable to the delivery protocol recited in our claims. The function of Flotte's high pressure impulse transients is to increase cellular absorption of *systemically* delivered drugs. Flotte, Col.3, lines 50-54; Col.4, lines 59-60. Aminoglycoside antibiotics having poor gut absorption are well-established for parenteral delivery, which results in systemic distribution, primarily within the extracellular fluid. Specification, p.1, lines 17-22. For such systemic delivery, the high-pressure impulse transients of Hu may well provide for the desired localized enhanced drug delivery. However, our claims are restricted to *enteric* delivery into the gut of the target patient, and our claims specifically require an aminoglycoside antibiotic having poor gut absorption. The methods of Flotte do not appear to have any application to enterically restricted drugs.

In my expert opinion, prior to the present disclosure, those skilled in this art did not have an expectation that such enterically delivered aminoglycosides having poor gut absorption could provide effective therapy for colorectal neoplasia.

I hereby declare that all statements made herein of my own knowledge are true and that all

statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity of the application and any patent issuing therefrom.

Date: 6.22.04



Prof. Jonathan Graff